Supply of SCID Assay Kits for NHS Newborn Blood Spot Screening

NHS England requires the provision of Spot-IT assay kits to support the ongoing in-service evaluation of Severe Combined Immuno-Deficiency (SCID) screening across three NHS laboratory sites. This contract is essential for meeting statutory newborn screening requirements and ensuring early detection of SCID in newborns, which directly improves patient outcomes through early intervention. The assay kits will be used to implement and evaluate the Spot-IT immunology testing methodology as part of the NHS Newborn Blood Spot screening program. This contract was awarded to Immunoivd AB and commenced on 1 October 2025. Suppliers should understand that this is a critical healthcare procurement supporting the expansion of newborn screening capabilities across England's laboratory network.